0
0
According to data from U.S. pharmaceutical company Novavax, the vaccine Nuvaxovid should also provide effective protection against the coronavirus variant Omicron. The company reported an effective immune response – even against the delta variant – in a release Thursday.
A third dose – called a booster – would increase that immune response even more, the first results of a study of the vaccine’s effectiveness in adolescents and as a booster showed. The immune response was as much as two to four times higher in adolescents than in adults.
Novavax also announced an Omicron-specific vaccine. “We expect clinical trials to begin in the first quarter of 2022,” said Gregory M. Glenn, president of research and development at Novavax. He said there is every indication that nuvaxovide “can play an important role in the ongoing fight against new variants.”
The data were obtained in a randomized, placebo-controlled Phase II study. They will now be submitted for publication and are expected to be posted here in the next few days.
- source: kleinezeitung.at/picture:
This post has already been read 708 times!
